Tetravalent bispecific fusion antibody for immunotherapy

Award Information
Agency:
Department of Health and Human Services
Branch
n/a
Amount:
$134,285.00
Award Year:
2004
Program:
SBIR
Phase:
Phase I
Contract:
1R43CA110297-01
Agency Tracking Number:
CA110297
Solicitation Year:
2004
Solicitation Topic Code:
n/a
Solicitation Number:
PHS2004-2
Small Business Information
IMMUNOMEDICS, INC.
IMMUNOMEDICS, INC., 300 AMERICAN RD, MORRIS PLAINS, NJ, 07950
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
ZHENGXING Qu
(973) 605-8200
TQU@IMMUNOMEDICS.COM
Business Contact:
CYNTHIA SULLIVAN
(973) 540-9595
CSULLIVAN@IMMUNOMEDICS.COM
Research Institution:
n/a
Abstract
DESCRIPTION (provided by applicant): Immunotherapy based on a naked monoclonal antibody (mAb), such as rituximab, has emerged as a safe and effective modality for treatment of indolent and aggressive non-Hodgkin's lymphomas (NHL) and chronic lymphocytic

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government